This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
by Zacks Equity Research
Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
by Zacks Equity Research
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
Top Research Reports for Apple, Tesla & T-Mobile US
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Tesla, Inc. (TSLA) and T-Mobile US, Inc. (TMUS), as well as a micro-cap stock Tucows Inc. (TCX).
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
by Zacks Equity Research
Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise investors to wait and watch before turning positive.
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
by Kinjel Shah
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
by Zacks Equity Research
The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
by Zacks Equity Research
NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Lilly Gets FDA Approval for Eczema Drug Ebglyss
by Zacks Equity Research
The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
by Zacks Equity Research
The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
by Ahan Chakraborty
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
by Zacks Equity Research
This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
Relay Stock Soars on Upbeat Data From Breast Cancer Study
by Zacks Equity Research
RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.
Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg
by Zacks Equity Research
BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg.
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug
by Zacks Equity Research
The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities.
Novartis to License VYGR's Capsid for Gene Therapy in Neurology
by Zacks Equity Research
NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target.
NVS or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
Novartis (NVS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Novartis (NVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Terns Surges 29.6% in Three Months: Will the Momentum Continue?
by Zacks Equity Research
TERN has outperformed the industry in the past three months on encouraging pipeline progress of its candidates. Positive data on obesity candidates should boost the stock further.
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
by Zacks Equity Research
NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
by Zacks Equity Research
Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.
Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug
by Zacks Equity Research
Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host disease.